Comparing Hyperion DeFi (NASDAQ:HYPD) and CNBX Pharmaceuticals (OTCMKTS:CNBX)

Hyperion DeFi (NASDAQ:HYPD) and CNBX Pharmaceuticals (OTCMKTS:CNBX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.

Valuation & Earnings

This table compares Hyperion DeFi and CNBX Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810,000.00	56.67	-$45.31 million	($11.80)	-0.34
CNBX Pharmaceuticals	N/A	N/A	N/A	($0.01)	-0.04

CNBX Pharmaceuticals has lower revenue, but higher earnings than Hyperion DeFi. Hyperion DeFi is trading at a lower price-to-earnings ratio than CNBX Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Hyperion DeFi and CNBX Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-129.97%	-92.39%
CNBX Pharmaceuticals	N/A	N/A	N/A

Institutional & Insider Ownership

25.8% of Hyperion DeFi shares are owned by institutional investors. Comparatively, 98.2% of CNBX Pharmaceuticals shares are owned by institutional investors. 10.9% of Hyperion DeFi shares are owned by insiders. Comparatively, 73.5% of CNBX Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for Hyperion DeFi and CNBX Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2	0	1	1	2.25
CNBX Pharmaceuticals	0	0	0	0	0.00

Hyperion DeFi currently has a consensus target price of $5.88, indicating a potential upside of 45.78%. Given Hyperion DeFi’s stronger consensus rating and higher possible upside, analysts clearly believe Hyperion DeFi is more favorable than CNBX Pharmaceuticals.

Summary

CNBX Pharmaceuticals beats Hyperion DeFi on 6 of the 11 factors compared between the two stocks.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

About CNBX Pharmaceuticals

CNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. The company is a subsidiary of Cannabics Inc.